The use of levofloxacin in the treatment of respiratory tract infection
Abstract
Increasing resistance among the common respiratory pathogens has encouraged assessment of alternative agents, for example, levofloxacin. Unlike earlier quinolones, levofloxacin has excellent activity against Streptococcus pneumoniae, including strains resistant to penicillin. Clinical trials show levofloxacin to be as effective as cephalosporins in acute exacerbation of chronic bronchitis and as effective as co-amoxiclav, cephalosporins or amoxycillin in community-acquired pneumonia. Levofloxacin is rarely associated with serious adverse events. Nausea, diarrhea, headache and rash are the most common adverse events but are observed less frequently than with some other new quinolones.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Photochemical behavior of levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.